

LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000, Fax: +91-79-4107-8062,

Website: www.lincolnpharma.com, E-Mail: info@lincolnpharma.com

Statement of Standalone and Consolidated Un-Audited Financial Results for the Quarter Ended on 30-June-2019.

[Rs. in Lakhs]

| Sr. No. | Particulars | Standalone | | | | Consolidated | | | |
|-----------|---|-----------------|-----------------|-----------------|------------------|-----------------|-----------------|------------------|------------------|
| | | Quarter Ended | | Year Ended | | Quarter Ended | | Year Ended | |
| | | 30/06/2019 | 31/03/2019 | 30/06/2018 | 31/03/2019 | 30/06/2019 | 31/03/2019 | 30/06/2018 | 31/03/2019 |
| | | [Un-Audited] | Refer Note 6 | [Un-Audited] | [Audited] | [Un-Audited] | Refer Note 6 | [Un-Audited] | [Audited] |
| 1 | Income | | | | | | | | |
| | A) Revenue From Operations | 9,458.95 | 7,746.05 | 9,663.16 | 35,304.25 | 9,681.26 | 7,932.09 | 9,982.16 | 36,618.10 |
| | B) Other Income | 157.95 | (59.43) | 224.03 | 657.54 | 129.44 | (87.23) | 229.65 | 565.08 |
| | Total Income | 9,616.90 | 7,686.62 | 9,887.19 | 35,961.79 | 9,810.70 | 7,844.86 | 10,211.81 | 37,183.18 |
| 2 | Expenses | | | | | | | | |
| | A) Cost of Material Consumed | 2,353.61 | 2,099.81 | 1,816.31 | 8,083.52 | 2,198.05 | 2,655.60 | 2,654.94 | 11,319.76 |
| | B) Purchase of Stock-In-Trade | 1,998.03 | 2,197.25 | 2,240.91 | 8,891.00 | 2,034.45 | 1,417.20 | 1,090.91 | 5,174.51 |
| | C) Changes In Inventories of Finished Goods, Stock-In-Trade and V | 110.53 | (114.96) | 420.91 | 733.30 | 101.47 | 47.52 | 723.29 | 1,050.16 |
| | D) Employee Benefits Expenses | 1,439.69 | 1,002.08 | 1,269.04 | 4,840.06 | 1,524.47 | 1,095.18 | 1,352.03 | 5,190.18 |
| | E) Finance Costs | 64.41 | 79.17 | 81.87 | 384.35 | 64.59 | 78.64 | 133.26 | 399.71 |
| | F) Depreciation and Amortisation Expense | 139.50 | 121.85 | 113.82 | 491.91 | 184.68 | 165.13 | 158.02 | 667.90 |
| | G) Other Expenses | 1,811.17 | 1,605.26 | 1,749.39 | 6,723.42 | 1,918.03 | 1,597.94 | 1,831.64 | 7,165.85 |
| | Total Expenses | 7,916.94 | 6,990.46 | 7,692.24 | 30,147.56 | 8,025.75 | 7,057.21 | 7,944.09 | 30,968.07 |
| 3 | Profit / (Loss) Before Exceptional Items & Tax (1-2) | 1,699.97 | 696.16 | 2,194.96 | 5,814.23 | 1,784.95 | 787.65 | 2,267.72 | 6,215.11 |
| 4 | Exceptional Items | Nil | Nil | Nil | Nil | Nil | Nil | Nil | Nil |
| 5 | Profit / (Loss) after Exceptional items but Before Tax (3-4) | 1,699.97 | 696.16 | 2,194.96 | 5,814.23 | 1,784.95 | 787.65 | 2,267.72 | 6,215.11 |
| 6 | Tax Expense | | | | | | | | |
| | A) Current Tax (Net) | 442.02 | 75.19 | 579.63 | 1,429.00 | 446.28 | 20.49 | 596.29 | 1,508.10 |
| | B) Short / Excess Provision of Income Tax of Previous Years | 69.31 | Nil | Nil | Nil | 69.31 | Nil | Nil | Nil |
| | C) Deferred Tax (Net) | (27.82) | (96.53) | 55.00 | (278.49) | 1.70 | (79.84) | 64.00 | (162.53) |
| 7 | Profit / (Loss) For The Period (5-6) | 1,216.45 | 717.50 | 1,560.33 | 4,663.72 | 1,267.66 | 847.00 | 1,607.43 | 4,869.54 |
| 8 | Attributable to: | | | | | | | | |
| | Non-Controlling Interest | Nil | Nil | Nil | Nil | 0.72 | 1.78 | 0.64 | 2.86 |
| | Owners of the Company | 1,216.45 | 717.50 | 1,560.33 | 4,663.72 | 1,266.94 | 845.22 | 1,606.79 | 4,866.68 |
| 9 | Other Comprehensive Income (Net of Tax) | 1.08 | (2.56) | 2.29 | 4.34 | 0.83 | (4.10) | 2.46 | 3.31 |
| 10 | Total Comprehensive Income | 1,217.53 | 714.94 | 1,562.62 | 4,668.06 | 1,267.77 | 841.12 | 1,609.25 | 4,869.99 |
| 11 | Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each) | 2,000.00 | 2,000.00 | 2,000.00 | 2,000.00 | 2,000.00 | 2,000.00 | 2,000.00 | 2,000.00 |
| 12 | Other Equity | | | | 24,260.40 | | | | 24,926.30 |
| 13 | Earnings Per Share (of Rs. 10/- Each) (Not Annualised) | | | | | | | | |
| | (A) Basic | 6.08 | 3.59 | 7.80 | 23.32 | 6.33 | 4.23 | 8.03 | 24.33 |
| | (B) Diluted | 6.08 | 3.59 | 7.80 | 23.32 | 6.33 | 4.23 | 8.03 | 24.33 |

| Notes: | |
|--------|--|
| 1 | The Financial Results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company in their respective meeting held on 14-Aug-2019. The auditor have carried out an Limited Review of the above said Financial Results. |
| 2 | The above results have been prepared in accordance with Indian Accounting Standards ('IND AS') notified under Section 133 of the Companies Act 2013, read together with the Companies (Indian Accounting standard) Rules, 2015. |
| 3 | The Adoption of IND AS 116 did not have any material impact on standalone results for three months ended June 30, 2019 |
| 4 | Figures for the previous periods have been regrouped and reclassified to conform to the classification of the current period, where necessary. |
| 5 | The Company has only one reportable segment i.e. Pharmaceuticals. |
| 6 | The Figures for the Last Quarter Results are the balancing figures between the Audited Figures in respect of the Full Financial Year and published Year to date figures up to the Third Quarter of the respective Financial Year. |
| 7 | Consolidated results includes results of its subsidiaries. |

FOR LINCOLN PHARMACEUTICALS LIMITED

Sd/-
MAHENDRA G. PATEL
MANAGING DIRECTOR
DIN: 00104706

PLACE: AHMEDABAD
DATE: AUGUST 14, 2019